Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195897
Status:
TERMINATED
Last Update Posted:
2016-08-22
First Post:
2005-09-12
Brief Title:
Early Assessment of Anthracycline-induced Cardiotoxicity CARDIOTOX
Sponsor:
Centre Henri Becquerel
Organization:
Centre Henri Becquerel
Study Overview
Official Title:
Early Assessment of Anthracycline-induced Cardiotoxicity Usefulness of Biochemical Markers and Ventricular Function Assessment
Status:
TERMINATED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No patients only 6 enrolled after 2 years
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkins and non-Hodgkins lymphomas However cumulative doses are limited by cardiotoxicity resulting in a marked left ventricular function impairment that may lead to heart failure
The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury troponin and NT-proBNP and structural changes on cardiac MR in predicting anthracycline cardiotoxicity
The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury troponin and NT-proBNP and structural changes on cardiac MR in predicting anthracycline cardiotoxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None